<DOC>
	<DOC>NCT01563302</DOC>
	<brief_summary>This is a Phase 1/2, open-label, dose-escalation, dose-expansion study for the treatment of patients with advanced cancers. Eligible patients with DLBCL or other advanced lymphomas will be enrolled into the dose-expansion cohort.</brief_summary>
	<brief_title>Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Aged 18 years or older Tumors that are relapsed or refractory to at least 1 prior anticancer systemic therapy and for which no standard therapy exists Expansion cohort only: Advanced lymphoma confirmed by histopathology Measurable or evaluable disease according to RECIST for solid tumors or according to IWRC for NHL tumors ECOG Performance Status less than or equal to 2 Life expectancy greater than 12 weeks in the opinion of the Investigator Any active or uncontrolled infection NYHA Grade II or greater congestive heart failure History of myocardial infarction within 6 months prior to screening Prior radiation therapy, chemotherapy, hormonal therapy, or immunotherapy within 4 weeks prior to screening or 5 halflives of the therapy, whichever is shorter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Advanced Cancers</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Advanced Lymphoma</keyword>
</DOC>